Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

54.6K
Overview
54.6K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Vaccines01:21

Vaccines

55
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
55
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

59
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
59
Vaccine Production01:23

Vaccine Production

85
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
85
Development of Immunocompetence01:22

Development of Immunocompetence

1.2K
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving cholera vaccination impact through advances in gut mucosal immunology: outcomes of a 2025 expert consultation.

Vaccine·2026
Same author

Heterologous prime-boost immunization combining parenteral and mucosal routes with different adjuvants mounts long-lived CD4+ T cell responses in lungs.

Frontiers in immunology·2025
Same author

A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™.

Vaccine·2025
Same author

Protection by natural cholera against later episodes of cholera over 10 years of follow-up in Matlab, Bangladesh: a retrospective cohort study.

The Lancet. Microbe·2025
Same author

Safety and immunogenicity of ETVAX®, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: a double-blinded, randomized, placebo-controlled trial amongst Finnish travellers to Benin, West Africa.

Journal of travel medicine·2023
Same author

A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.

Vaccine·2023

Related Experiment Video

Updated: Apr 12, 2026

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.8K

Vaccines against enteric infections for the developing world.

Cecil Czerkinsky1, Jan Holmgren2

  • 1CNRS, INSERM, Institut de Pharmacologie Moleculaire et Cellulaire, Université Nice Sophia Antipolis, 06103 Nice, France czerkinsky@ipmc.cnrs.fr.

Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|May 13, 2015
PubMed
Summary

Developing new mucosal adjuvants and intervention strategies can improve oral vaccines. This is crucial for enhancing enteric vaccine efficacy, especially in developing nations facing malnutrition and infection.

Keywords:
developing countryentericgutimmunitymucosavaccine

More Related Videos

Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 BSL-3 Conditions
07:59

Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 BSL-3 Conditions

Published on: September 10, 2021

3.7K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.6K

Related Experiment Videos

Last Updated: Apr 12, 2026

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.8K
Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 BSL-3 Conditions
07:59

Adapting Gastrointestinal Organoids for Pathogen Infection and Single Cell Sequencing under Biosafety Level 3 BSL-3 Conditions

Published on: September 10, 2021

3.7K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.6K

Area of Science:

  • Vaccinology
  • Immunology
  • Public Health

Background:

  • Oral vaccines, like the Sabin oral polio vaccine, offer programmatic advantages but face development challenges.
  • Key hurdles include limited understanding of early-life gut immunity, lack of mucosal adjuvants, and undefined correlates of protection.
  • Oral vaccine underperformance in children from developing countries is another significant concern.

Purpose of the Study:

  • To explore strategies for enhancing the efficacy of current and next-generation enteric vaccines.
  • To address the limitations hindering the development and deployment of effective oral vaccines.
  • To improve vaccine accessibility and impact in resource-limited settings.

Main Methods:

  • This study reviews existing knowledge and identifies key research gaps in mucosal vaccine development.
  • It highlights the need for novel mucosal adjuvants and intervention strategies.
  • Focuses on factors influencing oral vaccine performance in vulnerable populations.

Main Results:

  • Development of safe, effective mucosal adjuvants is critical for advancing vaccine technology.
  • Targeted intervention strategies can improve vaccine efficacy, particularly in regions with high disease burden.
  • Addressing factors like malnutrition and co-infections is essential for optimal vaccine response.

Conclusions:

  • Advancements in mucosal adjuvants and intervention strategies hold promise for improving enteric vaccine effectiveness.
  • Affordable, safe, and long-lasting oral vaccines are needed to confer herd immunity and control epidemics.
  • Future research should focus on overcoming barriers to oral vaccine efficacy in developing countries.